{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:37:57Z","timestamp":1758807477276},"reference-count":51,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAD"],"published-print":{"date-parts":[[2019,3,12]]},"abstract":"<jats:sec><jats:title\/><jats:p>Background: Hepatitis C virus (HCV) infection is a global burden. There is no peptide vaccine found as modality to cure the disease is available due to the weak cellular immune response and the limitation to induce humoral immune response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Five predominated HCV subtypes in Indonesia (1a, 1b, 1c, 3a, and 3k) were aligned and the conserved regions were selected. Twenty alleles of class I MHC including HLA-A, HLA-B, and HLAC types were used to predict the potential epitopes by using NetMHCPan and IEDB. Eight alleles of HLA-DRB1, together with a combination of 3 alleles of HLA-DQA1 and 5 alleles of HLA-DQB1 were utilized for Class II MHC epitopes prediction using NetMHCIIPan and IEDB. LBtope and Ig- Pred were used to predict B cells epitopes. Moreover, proteasome analysis was performed by NetCTL and the stability of the epitopes in HLA was calculated using NetMHCStabPan for Class I. All predicted epitopes were analyzed for its antigenicity, toxicity, and stability. Population coverage, molecular docking and molecular dynamics were performed for several best epitopes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The results showed that two best epitopes from envelop protein, GHRMAWDMMMNWSP (E1) and PALSTGLIHLHQN (E2) were selected as promising B cell and CD8+ T cell inducers. Other two peptides, LGIGTVLDQAETAG and VLVLNPSVAATLGF, taken from NS3 protein were selected as CD4+ T cell inducer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>This study suggested the utilization of all four peptides to make a combinational peptide vaccine for in vivo study to prove its ability in inducing secondary response toward HCV.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573409914666181003151222","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T14:39:47Z","timestamp":1538750387000},"page":"120-135","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Broad Spectrum Peptide Vaccine Design Against Hepatitis C Virus"],"prefix":"10.2174","volume":"15","author":[{"given":"Sherly Kurnia","family":"Dewi","sequence":"first","affiliation":[{"name":"Faculty of Biotechnology, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soegianto","family":"Ali","sequence":"additional","affiliation":[{"name":"Faculty of Biotechnology, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivitri Dewi","family":"Prasasty","sequence":"additional","affiliation":[{"name":"Faculty of Biotechnology, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"","year":"2017","unstructured":". Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/jvh.12476","volume":"22","author":"Sibley A.","year":"2015","unstructured":"Sibley A, Han KH, Abourached A, Lesmana LA, Makara M, Jafri W, Salupere R, Assiri AM, Goldis A, Abaalkhail F, Abbas Z, Abdou A, Al Braiki F, Al Hosani F, Al Jaberi K, Al Khatry M, Al Mulla MA, Al Quraishi H, Al Rifai A, Al Serkal Y, Alam A, Alavian SM, Alashgar HI, Alawadhi S, Al-Dabal L, Aldins P, Alfaleh FZ, Alghamdi AS, Al-Hakeem R, Aljumah AA, Almessabi A, Alqutub AN, Alswat KA, Altraif I, Alzaabi M, Andrea N, Babatin MA, Baqir A, Barakat MT, Bergmann OM, Bizri AR, Blach S, Chaudhry A, Choi MS, Diab T, Djauzi S, El Hassan ES, El Khoury S, Estes C, Fakhry S, Farooqi JI, Fridjonsdottir H, Gani RA, Ghafoor KA, Gheorghe L, Gottfredsson M, Gregorcic S, Gunter J, Hajarizadeh B, Hamid S, Hasan I, Hashim A, Horvath G, Hunyady B, Husni R, Jeruma A, Jonasson JG, Karlsdottir B, Kim DY, Kim YS, Koutoubi Z, Liakina V, Lim YS, L\u00f6ve A, Maimets M, Malekzadeh R, Mati\u010di\u010d M, Memon MS, Merat S, Mokhbat JE, Mourad FH, Muljono DH, Nawaz A, Nugrahini N, Olafsson S, Priohutomo S, Qureshi H, Rassam P, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Rozentale B, Sadik M, Saeed K, Salamat A, Sanai FM, Sanityoso SA, Sayegh RA, Sharara AI, Siddiq M, Siddiqui AM, Sigmundsdottir G, Sigurdardottir B, Speiciene D, Sulaiman A, Sultan MA, Taha M, Tanaka J, Tarifi H, Tayyab G, Tolmane I, Udin M, Umar M, Valantinas J, Vide\u010dnik-Zorman J, Yaghi C, Yunihastuti E, Yusuf MA, Zuberi BF, Schmelzer JD. The present and future disease burden of hepatitis C virus infections with today\u2019s treatment paradigm-volume 3.","journal-title":"J Viral Hepat"},{"key":"ref=3","first-page":"927","volume":"47","author":"Utsumi T.","year":"2016","unstructured":"Utsumi T, Pranawa LMI, Yano Y, Wahyuni RM, Istimagfiroh A, Amin M, Rinonce HT, Juniastuti WA, Tjempakasari A, Basuki W, Soetjipto HH, Hayashi Y. Prevalence and risk factors of hepatitis B and C infections among hemodialysis patients from private hemodialysis unit in Surabaya, Indonesia.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S2468-1253(16)30031-0","volume":"1","author":"Wait S.","year":"2016","unstructured":"Wait S, Kell E, Hamid S, Muljono DH, Sollano J, Mohamed R, Shah S. Al-Mahtab, Mamun.; Abbas, Z.; Johnston, J.; Tanwandee, T.; Wallace, J. Hepatitis B and hepatitis C in southeast and southern Asia: Challenges for governments.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.4066\/biomedicalresearch.29-17-2693","volume":"29","author":"Nurtjahyani S.P.","year":"2018","unstructured":"Nurtjahyani SP, Handajani R, Amin M, Hidayati D, Jadid N. Validation of anti HCV-hepatitis C identification in blood donors using PCR: Case study at Tuban East Java district, Indonesia.","journal-title":"Biomed Res"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","volume":"3","author":"Manns M.P.","year":"2017","unstructured":"Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection.","journal-title":"Nat Rev Dis Primers"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jhep.2014.09.009","volume":"61","author":"Baumert T.F.","year":"2014","unstructured":"Baumert TF, Fauvelle C, Chen DY, Lauer GM. A prophylactic hepatitis C virus vaccine: A distant peak still worth climbing.","journal-title":"J Hepatol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"e9832","DOI":"10.5812\/hepatmon.9832","volume":"14","author":"Ikram A.","year":"2014","unstructured":"Ikram A, Anjum S, Tahir M. identification and conservation analysis of B-cell and T-cell epitopes of hepatitis C virus 3a genotype enveloped glycoprotein 2 from Pakistan: A step towards heterologous vaccine design.","journal-title":"Hepat Mon"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/vaccines2030515","volume":"2","author":"Li W.","year":"2014","unstructured":"Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide vaccine: Progress and challenges.","journal-title":"Vaccines"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"8745","DOI":"10.1016\/j.vaccine.2011.07.132","volume":"29","author":"Toussaint N.C.","year":"2011","unstructured":"Toussaint NC, Maman Y, Kohlbacher O, Louzoun Y. Universal peptide vaccines \u2013 Optimal peptide vaccine design based on viral sequence conservation.","journal-title":"Vaccine"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.meegid.2016.05.009","volume":"43","author":"Ashraf N.M.","year":"2016","unstructured":"Ashraf NM, Bilal M, Mahmood MS, Hussain A, Mehboob MZ. analysis of putative HCV epitopes against Pakistani human leukocyte antigen \"background An approach towards development of future vaccines for Pakistani population.","journal-title":"Infect Genet Evol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1016\/j.vaccine.2006.03.009","volume":"24","author":"Fibras C.","year":"2006","unstructured":"Fibras C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects.","journal-title":"Vaccine"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"473909","DOI":"10.1155\/2015\/473909","volume":"2015","author":"Yutani S.","year":"2015","unstructured":"Yutani S, Ueshima K, Abe K, Ishiguro A, Eguchi J, Matsueda S, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kudo M, Noguchi M. Phase II study of personalized peptide vaccination with both a hepatitis C virus-Derived peptide and peptides from tumor-associated antigens for the treatment of HCV-Positive advanced hepatocellular carcinoma patients.","journal-title":"J Immunol Res"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.meegid.2014.01.008","volume":"22","author":"Xue J.","year":"2014","unstructured":"Xue J, Zhu H, Chen Z. Therapeutic vaccines against hepatitis C virus.","journal-title":"Infect Genet Evol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.virusres.2018.02.016","volume":"248","author":"Bartenschlager R.","year":"2018","unstructured":"Bartenschlager R, Baumert TF, Bukh J, Houghton M, Lemon SM, Lindenbach BD, Lohmann V, Moradpour D, Pietschmann T, Rice CM, Thimme R, Wakita T. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies.","journal-title":"Virus Res"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1093\/cid\/cis362","volume":"55","author":"Feinstone S.M.","year":"2012","unstructured":"Feinstone SM, Hu DJ, Major ME. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus.","journal-title":"Clin Infect Dis"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/gene.2013.25","volume":"14","author":"Kuniholm M.H.","year":"2013","unstructured":"Kuniholm MH, Anastos K, Kovacs A, Gao X, Marti D, Sette A, Greenblatt RM, Peters M, Cohen MH, Minkoff H, Gange SJ, Thio CL, Young MA, Xue X, Carrington M, Strickler HD. Relation of HLA class I and II supertypes with spontaneous clearance of hepatitis C virus.","journal-title":"Genes Immun"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fimmu.2016.00030","volume":"7","author":"Hickey M.J.","year":"2016","unstructured":"Hickey MJ, Valenzuela NM, Reed EF. Alloantibody generation and effector function following sensitization to Human Leukocyte Antigen.","journal-title":"Front Immunol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"957","DOI":"10.6026\/97320630008957","volume":"8","author":"Shehzadi A.","year":"2012","unstructured":"Shehzadi A, Ur-Rehman S, Husnain T. Selection of epitope-based vaccine targets of HCV genotype 1 of Asian origin: A systematic approach.","journal-title":"Bioinformation"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-016-0288-x","volume":"8","author":"Nielsen M.","year":"2016","unstructured":"Nielsen M, Andreatta M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets.","journal-title":"Genome Med"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0014-5793(90)80535-Q","volume":"276","author":"Kolaskar A.S.","year":"1990","unstructured":"Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens.","journal-title":"FEBS Lett"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1755-8794-8-S4-S3","volume":"8","author":"Huang W.L.","year":"2015","unstructured":"Huang WL, Tsai MJ, Hsu KT, Wang JR, Chen YH, Ho SY. Prediction of linear B-cell epitopes of hepatitis C virus for vaccine development.","journal-title":"BMC Med Genomics"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.4049\/jimmunol.171.4.1741","volume":"171","author":"Peters B.","year":"2003","unstructured":"Peters B, Bulik S, Tampe R, Van-Endert PM, Holzh\u00fctter HG. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors.","journal-title":"J Immunol"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2567.2010.03300.x","volume":"130","author":"Lundegaard C.","year":"2010","unstructured":"Lundegaard C, Lund O, Buus S, Nielsen M. Major histocompatibility complex class I binding predictions as a tool in epitope discovery.","journal-title":"Immunology"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"Trott O.","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading.","journal-title":"J Comput Chem"},{"key":"ref=26","first-page":"19","volume":"1","author":"Abraham M.J.","year":"2004","unstructured":"Abraham MJ, Teemu M, Roland S, Szil\u00e1rd P, Jeremy C, Berk H, Erik L. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers.","journal-title":"SoftwareX"},{"key":"ref=27","first-page":"61","volume":"4","author":"Marwan M.B.","year":"2016","unstructured":"Marwan MB, Afra AF, Salma S, Wafa AM, Duaa AN, Samar AAAA, Entissar MEA, Abdah AA, Ranya OA, Mohamed AS. Immunoinformatics predication and modeling of epitope-based peptide vaccine against virulent newcastle disease viruses.","journal-title":"Am J Infec Dis Microbiol"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/601943","volume":"2013","author":"Molero-Abraham M.","year":"2013","unstructured":"Molero-Abraham M, Lafuente EM, Flower DR, Reche PA. Selection of conserved epitopes from hepatitis C virus for pan-populational stimulation of T-cell responses.","journal-title":"Clin Dev Immunol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2017.10.079","volume":"36","author":"von Delft A.","year":"2018","unstructured":"von Delft A, Donnison TA, Louren\u00e7o J, Hutchings C, Mullarkey CE, Brown A, Pybus OG, Klenerman P, Chinnakannan S, Barnes E. The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.","journal-title":"Vaccine"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/intimm\/8.5.651","volume":"8","author":"Wentworth P.A.","year":"1996","unstructured":"Wentworth PA, Sette A, Celis E, Sidney J, Southwood S, Crimi C, Stitely S, Keogh E, Wong NC, Livingston B, Alazard D, Vitiello A, Grey HM, Chisari FV, Chesnut RW, Fikes J. Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome.","journal-title":"Int Immunol"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0198-8859(98)00080-9","volume":"59","author":"Alexander J.","year":"1998","unstructured":"Alexander J, Del Guercio MF, Fikes JD, Chesnut RW, Chisari FV, Chang KM, Appella E, Sette A. Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers IFN-gamma release in absence of detectable cytopathicity.","journal-title":"Hum Immunol"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00705-015-2334-1","volume":"160","author":"Shawky H.","year":"2015","unstructured":"Shawky H. Expression, immunogenicity and diagnostic value of envelope proteins from an Egyptian hepatitis C virus isolate.","journal-title":"Arch Virol"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1590\/0074-02760140441","volume":"110","author":"Urbaczek A.C.","year":"2015","unstructured":"Urbaczek AC. Recombinant hepatitis C virus-envelope protein 2 interactions with low-density lipoprotein\/CD81 receptors.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.32607\/20758251-2015-7-1-87-97","volume":"7","author":"Orlova O.V.","year":"2015","unstructured":"Orlova OV. The role of HCV E2 protein glycosylation in functioning of virus envelope proteins in insect and mammalian cells.","journal-title":"Acta Naturae"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"11080","DOI":"10.1128\/JVI.01590-14","volume":"88","author":"Ziegler S.","year":"2014","unstructured":"Ziegler S. Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells.","journal-title":"J Virol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2567.2010.03268.x","volume":"130","author":"Nielsen M.","year":"2010","unstructured":"Nielsen M, Lund O, Buus S, Lundegaard C. MHC Class II epitope predictive algorithms.","journal-title":"Immunology"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nri3818","volume":"15","author":"Roche P.A.","year":"2015","unstructured":"Roche PA, Kazuyuki F. The ins and outs of MHC class II- mediated antigen processing and presentation.","journal-title":"Nat Rev Immunol"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1743-422X-11-187","volume":"11","author":"Gededzha M.P.","year":"2014","unstructured":"Gededzha MP, Mphahlele MJ, Selabe SG. Prediction of T-cell epitopes of hepatitis C virus genotype 5a.","journal-title":"Virol J"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/hep.23515","volume":"51","author":"Kuniholm M.H.","year":"2010","unstructured":"Kuniholm MH. Specific HLA class I and II alleles associated with hepatitis C virus viremia.","journal-title":"Hepatology"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/jmv.24211","volume":"87","author":"Samimi-Rad K.","year":"2015","unstructured":"Samimi-Rad K. Association of HLA class II alleles with hepatitis C virus clearance and persistence in thalassemia patients from Iran.","journal-title":"J Med Virol"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/jvh.12573","volume":"23","author":"El-Bendary M.","year":"2016","unstructured":"El-Bendary M. Associations of human leucocyte antigen class II-DQB1 alleles with hepatitis C virus infection in Egyptian population: A multicentre family-based study.","journal-title":"J Viral Hepat"},{"key":"ref=42","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29531","volume":"2017","author":"Lee M.H.","year":"2017","unstructured":"Lee MH. Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by HCV genotypes: A genome-wide association study.","journal-title":"Hepatology"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.4161\/hv.29177","volume":"10","author":"Abdel-Hady K.M.","year":"2014","unstructured":"Abdel-Hady KM. Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: An accelerated approach toward epitope-driven vaccine development.","journal-title":"Hum Vaccin Immunother"},{"key":"ref=44","unstructured":"(15) pii, eaal5296."},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1074\/mcp.M112.020800","volume":"11","author":"Buss S.","year":"2012","unstructured":"Buss S. High-resolution mapping of linear antibody epitopes using ultrahigh-density peptide microarrays.","journal-title":"Mol Cell Proteomics"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"e0138756","DOI":"10.1371\/journal.pone.0138756","volume":"10","author":"Deng K.","year":"2015","unstructured":"Deng K. Antibodies targeting novel neutralizing epitopes of hepatitis C virus glycoprotein preclude genotype 2 virus infection.","journal-title":"PLoS One"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1365-2893.2002.00358.x","volume":"9","author":"Olenina L.V.","year":"2002","unstructured":"Olenina LV. Mapping and characterization of B cell linear epitopes in the conservative regions of hepatitis C virus envelope glycoproteins.","journal-title":"J Viral Hepat"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"12923","DOI":"10.1128\/JVI.02052-12","volume":"86","author":"Potter J.A.","year":"2012","unstructured":"Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, Foung SK, Taylor GL, Patel AH. Toward a hepatitis C virus vaccine: The structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody.","journal-title":"J Virol"},{"key":"ref=49","first-page":"31","volume":"5","author":"Dunlop J.I.","year":"2015","unstructured":"Dunlop JI, Owsianka AM, Cowton VM, Patel AH. Current and future prophylactic vaccines for hepatitis C virus.","journal-title":"Vaccine Development and Therapy"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/vaccines3020203","volume":"3","author":"Ip P.P.","year":"2015","unstructured":"Ip PP, Nijman HW, Daemen T. Epitope prediction assays combined with validation assays strongly narrows down putative cytotoxic t lymphocyte epitopes.","journal-title":"Vaccines (Basel),"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.vaccine.2009.12.072","volume":"28","author":"Firbas C.","year":"2010","unstructured":"Firbas C. Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine.","journal-title":"Vaccine"}],"container-title":["Current Computer-Aided Drug Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/165917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T02:07:23Z","timestamp":1720663643000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/165917\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,12]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573409914666181003151222","relation":{},"ISSN":["1573-4099"],"issn-type":[{"value":"1573-4099","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}